Results of screening 1.9 million Texas newborns for 21-hydroxylase- deficient congenital adrenal hyperplasia

Pediatrics

Volumn 101, Issue 4 I, 1998, Pages 583-590

  Therrell Jr , Bradford L ^a   Berenbaum, Sheri A ^b   Manter Kapanke, Valerie ^b   Simmank, Jennifer ^a   Korman, Kristina ^b   Prentice, Linda ^a   Gonzalez, Jose ^c   Gunn, Sheila ^d  

^a TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN S MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

17 hydroxyprogesterone; 21 hydroxylase deficiency; Congenital adrenal hyperplasia; Newborn screening

Indexed keywords

HYDROXYPROGESTERONE; STEROID 21 MONOOXYGENASE;

ADRENAL INSUFFICIENCY; ARTICLE; BLOOD SAMPLING; CLINICAL PROTOCOL; CONGENITAL ADRENAL HYPERPLASIA; ELECTROLYTE DISTURBANCE; FEMALE; HUMAN; INCIDENCE; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SALT LOSING NEPHRITIS; VIRILIZATION;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL HYPERPLASIA, CONGENITAL; FEMALE; HUMANS; INFANT, NEWBORN; MALE; NEONATAL SCREENING; TEXAS;

EID: 2642620230     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.101.4.583     Document Type: Article

References (38)

1. Pang S, Wallace MA, Hofman L, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988;81:866-874
2. Pang S, Clark A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening. 1993;2:105-139
3. Therrell BL. National screening status report. Infant Screening. 1997;20:7
4. New MI. Clinical and endocrinological aspects of 21-hydroxylase deficiency. Ann NY Acad Sci. 1985;458:1-27
5. New MI, White PC, Pang S, Dupont B, Speiser PW. The adrenal hyperplasias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill;1989;2: 1881-1917
6. Miller WL. The adrenal cortex. In: Rudolph AM, Hoffman JIE, Rudolph CD, Sagan P, eds. Rudolph's Pediatrics. 20th ed. Stamford, CT: Appleton and Lange; 1996:1711-1742
7. Morel Y, Miller WL. Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. In: Harris H, Hirshhorn K, eds. Advances in Human Genetics. New York, NY: Plenum; 1991;20:1-68
8. Miller WL. Genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1994;710:241-246
9. Speiser PW, Dupont B, Rubinstein P, et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet. 1985;37: 650-667
10. Azziz R, Dewailly D, Owerbach D. Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab. 1994;78:810-815
11. Wedell A, Thilen A, Ritzen EM, Stengler B, Luthman H. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab. 1994;710:1145-1152
12. White PC, New MI. Genetic basis of endocrine disease 2: congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1992;74:6-11
13. Frankenburg WK. Selection of diseases and tests in pediatric screening. Pediatrics. 1974;54:612-616
14. Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. Microfilter paper method for 17-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1977;45:1003-1008
15. Hofman LF, Pang S. Screening newborns for congenital adrenal hyperplasia. In: Therrell BL, ed. Laboratory Methods for Neonatal Screening. Washington, DC: American Public Health Association; 1993:155-610
16. Larsson A, Thilen A, Hagenfeldt L, von Dobeln U, Guthenberg C. Screening of half a million Swedish newborn infants for congenital adrenal hyperplasia. Screening. 1992;1:159-166
17. Suwa S. Nationwide survey of neonatal mass screening for congenital adrenal hyperplasia in Japan. Screening. 1994;3:141-151
18. Levine GL, Therrell BL. Second testing for hypothyroidism. Pediatrics. 1986;86:375-376. Letter
19. Therrell BL, Nickles CA, Dziuk PE. Neonatal hypothyroid screening in Texas. Ligand Rev. 1980;2:12-14
20. Therrell BL, Berenbaum SA. Screening for congenital adrenal hyperplasia - the need for uniform data collection. Infant Screening. 1992;15: 18-23
21. Prader A. Der genitalbefund beim pseudohermaphroditismus femininus des kongenitalen adrenogenitalen syndroms. Helv Paediatr Acta. 1954;3:231-248
22. New MI, Lorenzen F, Lerner AJ, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab. 1983;57:320-326
23. New MI, Gertner JM, Speiser PW, del Balzo P. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Acta Paediatr Jpn. 1988;30:79-88
24. Balsamo A, Cacciari E, Piazzi S, et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics. 1996;98:362-367
25. Larsson A, von Döbeln U, Guthenberg C, Hagenfeldt L, Thilen A. Congenital adrenal hyperplasia - unsolved questions in neonatal screening. In: Farriaux J-P, Dhondt J-L, eds. New Horizons in Neonatal Screening. Amsterdam, The Netherlands: Elsevier; 1994:155-160
26. Dorche C, Dhondt JL, Bozon D, Rolland MO, David M, Farriaux JP. Systematic neonatal screening for congenital adrenal hyperplasia: report of a pilot study in two centers in France. In: Therrell BL, ed. Advances in Neonatal Screening. Amsterdam, The Netherlands: Elsevier; 1987:289-292
27. Hofman LF. Screening infants for CAH: the Washington experience. In: Therrell BL, ed. Advances in Neonatal Screening. Amsterdam, The Netherlands: Elsevier; 1987:287-288
28. Speiser PW, Dupont J, Zhu D, et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest. 1992;90:584-595
29. Wedell A, Luthman H. Steroid 21-hydroxylase deficiency: two additional mutations in salt-wasting disease and rapid screening of disease-causing mutations. Hum Mol Genet. 1993;2:499-504
30. Thilen A, Woods KA, Perry LA, Savage MO, Wedell A, Ritzen EM. Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency. Acta Paediatr. 1995;84:894-898
31. Jääskelainen J, Voutilainen R. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatr Res. 1997;41:30-33
32. Van Wyk JJ, Gunther DF, Ritzen EM, et al. The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1996;81:3180-3189
33. Cutfield WS, Webster D. Newborn screening for congenital adrenal hyperplasia in New Zealand. J Pediatr. 1995;126:120-121
34. Nivelon JL, Toublanc JE. French association's experience with screening for congenital adrenal hyperplasia. In: Farriaux J-P, Dhondt J-L, eds. New Horizons in Neonatal Screening. Amsterdam, The Netherlands: Elsevier; 1994:173-176
35. Larsson A, Hagenfeldt L, von Döbeln U, Curstedt T, Gustafsson J, Svensson E. Neonatal screening for congenital adrenal hyperplasia using 17-hydroxyprogesterone assay in filter paper blood spots. Horm Res. 1988;30:235-240
36. Torresani T, Grüters A, Scherz R, Burckhardt JJ, Harras A, Zachman M. Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17-α-hydroxyprogesterone to gestational age. Screening. 1994;3:77-84
37. Fujieda K, Matsuura N, Takasugi N, Fukushi M, Arai O, Mizushima Y. Five years' experience of newborn screening for congenital adrenal hyperplasia in Sapporo. In: Therrell BL, ed. Advances in Neonatal Screening. Amsterdam, The Netherlands: Elsevier; 1987:281-286
38. 4-steroids measured by HPLC-UV spectrometry in neonatal patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res. 1990;33:27-34